<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956044</url>
  </required_header>
  <id_info>
    <org_study_id>THR-1442-C-453</org_study_id>
    <nct_id>NCT02956044</nct_id>
  </id_info>
  <brief_title>Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin</brief_title>
  <official_title>A Phase 1, Open-label, Randomized, Three-period, Crossover Study to Evaluate Pharmacokinetic Interaction Between Bexagliflozin Tablets and Metformin, Glimepiride, or Sitagliptin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the drug-drug interaction in your body when given the
      study drug, bexagliflozin, with three commonly used ant-diabetic medications, metformin,
      glimepiride or sitagliptin. The study will also evaluate how safe the study drug is and how
      well the study drug is tolerated when taken with metformin, glimepiride or sitagliptin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum observed plasma concentration)</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax (Time of maximum observed plasma concentration)</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 (Apparent terminal elimination half-life)</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf (Area under the plasma concentration-time curve from Time 0 to infinity)</measure>
    <time_frame>Up to 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary Glucose Excretion 0-12 hr</measure>
    <time_frame>0-12 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Glucose Excretion 12-24 hr</measure>
    <time_frame>12-24 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Glucose Excretion 24-36 hr</measure>
    <time_frame>24-36 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Glucose Excretion 36-48 hr</measure>
    <time_frame>36-48 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by adverse events</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group 1: Bexagliflozin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Metformin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Bexagliflozin + Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Bexagliflozin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Glimepiride alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Bexagliflozin + Glimepiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Bexagliflozin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Sitagliptin alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Bexagliflozin + Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bexagliflozin</intervention_name>
    <description>Bexagliflozin tablets, 20 mg</description>
    <arm_group_label>Group 1: Bexagliflozin alone</arm_group_label>
    <arm_group_label>Group 1: Bexagliflozin + Metformin</arm_group_label>
    <arm_group_label>Group 2: Bexagliflozin alone</arm_group_label>
    <arm_group_label>Group 2: Bexagliflozin + Glimepiride</arm_group_label>
    <arm_group_label>Group 3: Bexagliflozin alone</arm_group_label>
    <arm_group_label>Group 3: Bexagliflozin + Sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>1000 mg metformin</description>
    <arm_group_label>Group 1: Metformin alone</arm_group_label>
    <arm_group_label>Group 1: Bexagliflozin + Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>4 mg glimepiride</description>
    <arm_group_label>Group 2: Glimepiride alone</arm_group_label>
    <arm_group_label>Group 2: Bexagliflozin + Glimepiride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>100 mg sitagliptin</description>
    <arm_group_label>Group 3: Sitagliptin alone</arm_group_label>
    <arm_group_label>Group 3: Bexagliflozin + Sitagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2

          2. Subjects who are non-smokers for at least 3 months prior to screening

          3. Subjects who are willing and able to be confined to the clinical research facility as
             required by the protocol

        Exclusion Criteria:

          1. Subjects with a clinically significant history of allergy to drugs or latex.

          2. Subjects with a history of alcohol or drug dependence in the past 12 months.

          3. Subjects who have donated a significant amount of blood in the past 2 months

          4. Female subjects who are pregnant or breastfeeding

          5. Subjects who are not willing to use an adequate form of birth control during the study
             and for 30 days after discharge from clinic

          6. Subjects who have taken an investigational drug in the past 30 days or 7 half-lives of
             the investigational drug, whichever is longer

          7. Subjects who had previously received anti-diabetic medication, including metformin,
             sitagliptin, glimepiride or drugs of the same class (i.e. biguanides, DPP-4 inhibitors
             or sulfonylureas), or SGLT2 inhibitors, in the past 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mason Freeman, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2016</study_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

